

## Special Issue

# Enteroviruses: Advances in Virology, Pathogenesis, and Vaccine R&D

### Message from the Guest Editors

Enteroviruses are a diverse group of RNA viruses within the Picornaviridae family, responsible for various human diseases. Specific serotypes, such as enterovirus-71 (EV-71) and coxsackieviruses, are significant causes of hand, foot, and mouth disease (HFMD). This Special Issue aims to bring together the latest research and scientific advances on enteroviruses, covering virology, molecular epidemiology, viral pathogenesis, immunological responses, and vaccine R&D. Original research articles and reviews are welcome, which research areas may include (but are not limited to) the following:

- Enterovirus classification, phylogenetics, genomic analysis, and evolutionary dynamics
- Molecular and cellular mechanisms of viral pathogenesis
- Surveillance systems, outbreak investigation, and transmission patterns
- Host immune responses and correlates of protection
- Vaccine development and evaluation, especially multivalent (multi-serotype) vaccines and novel platforms such as mRNA and virus-like particle (VLP) technologies
- Epidemiological trends and public health strategies
- Studies focusing on poliovirus, EV-71, coxsackieviruses, and other clinically relevant enteroviruses

### Guest Editors

Dr. Yang Song

Dr. Naiying Mao

Dr. Jinbo Xiao

### Deadline for manuscript submissions

31 December 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/238307](https://mdpi.com/si/238307)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).